Antibody Discovery News and Research

RSS

New design strategy marks a potential advance in the fight against Alzheimer's disease

Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells - a potential advance in the fight against Alzheimer's disease.

26 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020

OXGENE™ reports third consecutive year of 100% year on year revenue growth

OXGENE™ has more than doubled its annual revenue in the financial year just closed, in the third consecutive year of 100% year on year revenue growth.

From OXGENE 6 May 2020

Israeli scientists discover monoclonal antibody that neutralizes SARS-CoV-2

Now, in a significant medical breakthrough, Israel's Institute for Biological Research Institute (IIBRI) has wrapped up the development of a potential treatment for the coronavirus disease. The scientists say they have identified an antibody that neutralizes SARS-CoV-2.

5 May 2020

Scientists are developing synthetic COVID-19 antibody to treat sick patients

A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.

24 Apr 2020

Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis

Accelerating antibody discovery using picodroplet technology for single cell analysis to condense discovery times down to 1-2 days.

From Sphere Fluidics 22 Apr 2020

Berkeley Lights Announces GEPAD to Attack COVID-19 and Other Viruses

Today Berkeley Lights, Inc., announced the GEPAD with the aim to accelerate the discovery of neutralizing antibodies from patient blood samples.

From PhenomeX 26 Mar 2020

Celltrion announces key milestones in its efforts to fight COVID-19

Celltrion Group today announced key milestones in its efforts to fight the 2019 novel coronavirus (COVID-19) pandemic.

23 Mar 2020

DSI alumni use computational design to quickly discover treatments for COVID-19

Two graduates of the Data Science Institute at Columbia University are using computational design to quickly discover treatments for the coronavirus.

21 Mar 2020

Berkeley Lights Launches Cell Line Development 2.0 Workflow to Find Top Clones for Complex Antibody Therapeutics

The Opto™ Cell Line Development 2.0 workflow generates, in just days, the best production cell lines for complex antibody therapeutics.

From PhenomeX 10 Mar 2020

Carterra closes financing round for continued growth of the LSA platform for next generation antibody discovery

Carterra Inc., the world leader in high-throughput antibody screening and characterization, has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners.

From Carterra Inc. 23 Jan 2020

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Turbine, a simulation-first drug discovery company, today announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.

21 Jan 2020

Integral Molecular announces panel of P2X7 antibodies for autoimmune disorders

Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that is the target for autoimmune disorders including atopic dermatitis and glomerulonephritis.

10 Jan 2020

IONTAS, Adaptate Biotherapeutics join forces to generate and optimize antibodies for novel cancer targets

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

From IONTAS 4 Dec 2019

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies.

From Sartorius 3 Dec 2019

Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities

Sphere Fluidics and Peak Analysis and Automation, announce optimization of the Single Cell Analysis System through integration with automated plate handler.

From Sphere Fluidics 7 Nov 2019